MAR

Active Biotech acquires exclusive rights to patents of tasquinimod in combination therapy

Lund, May 22, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces it has entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination…

Active Biotech announces outcome of the Company’s rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…

Active Biotech announces a rights issue of approximately SEK 51 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…

Active Biotech Interim Report Q3 2023

THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…

Active Biotech Interim Report Q2 2023

SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…

Active Biotech Interim Report Q1 2023

FIRST QUARTER IN BRIEF Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30) Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances New preclinical data on naptumomab published  EVENTS AFTER THE END OF THE PERIOD Safety and…

Active Biotech Year End Report 2022

FOURTH QUARTER IN BRIEF Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24) Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13) Phase I Multiple dose study of laquinimod recruited final patient OTHER SIGNIFICANT EVENTS JAN…

Active Biotech confirms positive clinical safety profile of laquinimod eye drops

Lund, January 30, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the completion of the phase I clinical study testing the safety and tolerability of the newly developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at…

Active Biotech Interim Report Q3 2022

THIRD QUARTER IN BRIEF Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4) The first part of the multiple dose of laquinimod eye…

Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US

Lund, October 24, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be issued on 25 October, 2022, under…

Active Biotech announces final outcome of the Company’s rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW Active…

Active Biotech announces a rights issue of approximately SEK 55 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The board…

Active Biotech Interim Report Q2 2022

SECOND QUARTER IN BRIEF Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26) FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18) Successful completion…

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Lund, June 1, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung…

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

  Lund May 18, 2022 – Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for…

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under…

Active Biotech Interim Report Q1 2022

FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01) First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07) Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9) EVENTS…

Correction: Active Biotech Year End Report 2021

The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15,2 M. The error has been discovered in connection with the finalization of the Annual…

Active Biotech: Year End Report 2021

FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular proved to be a busy period, with continued strong development with all the prioritized projects in our portfolio. Tasquinimod Clinical…

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Lund, February 9, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).…

Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma

Lund Sweden, February 7, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma. In this part of the study treatment with tasquinimod will be tested…

First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  

Lund, December 10, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod. Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and…

Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lund, November 9, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today a presentation on naptumomab estafenatox (naptumomab, NAP), at the Society for Immunotherapy of Cancer (SITC 2021) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center in Washington D.C…

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Lund, November 4, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021. The results that will be highlighted…

Active Biotech Interim report January – September 2021  

        “We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD QUARTER IN BRIEF •  Active Biotech provided status update of its clinical naptumomab project on July 5• …

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Lund, October 20, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox (naptumomab), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The phase IIa, open label…

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when…

Active Biotech AB Interim report January – June 2021

Good progress in the projects towards important clinical events SECOND QUARTER IN BRIEF Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab EVENTS AFTER THE END OF THE PERIOD Active Biotech provided status update on the progress in its clinical naptumomab project Active…

Active Biotech AB Interim report January – March 2021

Financing completed and good progress in the projects First quarter in brief Agreement signed for manufacturing of a topical ophthalmic formulation and capsules of laquinimod for use in clinical studies Activities are ongoing according to plan in the naptumomab and tasquinimod projects Corporate Rights issue prospectus published on January 5,…

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Phase IIa trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021 Lund Sweden, April 19, 2021 – Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration…

Active Biotech Year-end report January – December 2020

       New strategic R&D plan implemented and financed Fourth quarter in briefTasquinimod The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in December Patent granted in China in October regarding treatment of multiple myeloma…

Active Biotech’s rights issue heavily oversubscribed

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW   …

Active Biotech publishes prospectus and certain new financial information included in the prospectus

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The…

Active Biotech Receive Milestone Payment From Neotx

  PRESS RELEASE, Lund Sweden, December 11, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) Active Biotech AB (publ) today announce a milestone payment of USD 750 000 from the partner NeoTX Therapeutics (NeoTX) under the terms of license agreement on the immunotherapy naptumomab. Based on preclinical data and the previous…

Active Biotech announces the final terms of the rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW On 5…

Correction to previous pressrelease: Active Biotech updates its clinical strategy and projected milestones

Correction: All information was not included in previous pressrelease. PRESS RELEASE, Lund Sweden, November 24, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics.…

ACTIVE BIOTECH UPDATES ITS CLINICAL STRATEGY AND PROJECTED MILESTONES

Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics. Investors, analysts and media are invited to today’s virtual Capital Markets Day where the current status and future developments of the company’s…

Active Biotech announces rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW Active Biotech…

Active Biotech Interim report January – September 2020

IMPORTANT EVENTS DURING THE THIRD QUARTERTasquinimod First patient dosed in the monotherapy part of the phase 1b/2a study in multiple myeloma The clinical study design for multiple myeloma will be presented at the virtual American Society of Hematology meeting 2020 in December Patents regarding treatment of acute leukemia granted in…

Active Biotech Interim Report January – June 2020

                                                                                                                                                  Second quarter in brief Dr Elaine Sullivan, Dr Aleksandar Danilovski and Dr Axel Glasmacher were appointed as new members of the Board at the Annual General Meeting on May 19 Active Biotech provided status update in the portfolio projects New…

Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma

Lund Sweden, August 3, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the first patient has been dosed in the phase 1b/2a clinical study of tasquinimod for treatment of relapsed or refractory multiple myeloma. The study, which is planned to recruit up to 54 patients, will establish a…

Active Biotech provides status update in the portfolio projects

Lund, June 3, 2020 – Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated update is provided as a midterm replacement of the Capital Markets Day previously announced for May 19, which we now instead are…

Active Biotech Interim Report January – March 2020

First quarter in brief Active Biotech announces new direction Patent regarding use of tasquinimod in the treatment of multiple myeloma granted in Japan Events after the end of the period Due to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the…

Active Biotech AB – Year-end report January – December 2019

                                                                                                   …

Active Biotech Interim report January – September 2019

                                                                                                   …

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Lund Sweden, November 5, 2019 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that its partner NeoTX will present new preclinical data on the drug candidate naptumomab estafenatox (naptumomab, ANYARA) at the scientific conference at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting being held November 6-10, 2019 in…

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

Lund Sweden, October 28 2019 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and NeoTX announce that the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® (durvalumab)  for the treatment of advanced or metastatic solid tumors. The study…

Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

  Lund Sweden, September 23, 2019 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that new data from exploratory analysis of the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the International congress of Parkinson’s disease and Movement disorders in Nice, France, September 22-26, 2019. The…

Active Biotech AB: Interim report January – June 2019

         Significant events during the second quarter In accordance with the Board’s proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company’s property to Estea AB Active Biotech completed the sale of the property, Forskaren 1, to Estea AB on…

The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board

PRESS RELEASE Lund  2 May, 2019 –Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that the Election Committee of Active Biotech AB (publ) proposes that Michael Shalmi and Uli Hacksell are appointed new members of the Board of Directors and that Michael Shalmi is appointed Chairman of the Board of Directors. Mats Arnhög…